Insilicos Announces Breakthrough Proteomics Software Platform

Seattle, 29 May 2006 - Seattle life sciences company Insilicos today announced the launch of Insilicos Proteomics Pipeline (IPP), the first high-performance software system for the identification and analysis of proteomics data. Proteomics is a key technology behind the development of new biotech drugs and diagnostic tests.
IPP is the result of an open-source collaboration led by the Institute for Systems Biology (ISB). "This offering by Insilicos will allow more people to take advantage of the proteomics approaches that we pioneered at the Institute for Systems Biology," said ISB cofounder and internationally renowned biologist Dr. Ruedi Aebersold. "The performance and ease of use of this product is a significant advance, and will contribute to the goal of consistent and transparent analysis of proteomics data."
Insilicos developed IPP as a result of its role as the leading outside contributor and collaborator on the ISB's proteomics project. IPP takes the groundbreaking work of the ISB, and makes it run up to 20 times faster —fast enough to run on an inexpensive laptop. "Proteomics will revolutionize human health, but software has been a key bottleneck," said Insilicos president Erik Nilsson. "Now IPP brings that power within reach of anyone with a laptop."
The ISB originally developed the Trans-Proteomic Pipeline tools as part of a grant funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. In 2005, Insilicos and the ISB received a grant from the NHLBI to further develop the ISB's software for use by a broad range of scientists.

Insilicos LLC is a biomarker discovery and diagnostic development company, concentrating on cardiovascular disease.

For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' 'PreClue," and 'Life Science Software' are trademarks of Insilicos LLC.